Recent Finacing
Recent Raise
PvP Biologics develops KumaMax, an orally administered enzyme—licensed from UW’s Institute for Protein Design—to enzymatically degrade immune-reactive gluten in the stomach and advance through phase 1 proof-of-principle studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor